VCELMEDIUM SIGNALFINANCIAL10-K

VCEL delivered strong revenue growth of 16.5% while substantially improving profitability and reducing capital expenditures by more than half.

The company appears to be entering a more mature operational phase, with revenue growth translating to meaningfully higher net income while capital spending declined significantly from $64M to $27M. The substantial improvement in profitability alongside reduced capex suggests VCEL is generating stronger returns on its existing asset base.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

VCEL demonstrated solid top-line growth with revenue increasing 16.5% to $276.3M and gross profit expanding 19.5% to $205.6M, indicating improving operational efficiency. Net income grew substantially while capital expenditures dropped meaningfully from $64M to $27M, suggesting the company has moved past a heavy investment phase. The balance sheet strengthened with cash rising 34.3% to $100.1M and stockholders' equity increasing 21.5%, reflecting the company's improved profitability and cash generation.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+63.9%
$366K$600K

Interest expense surged 63.9% — significant debt increase or rising rates materially impacting earnings.

Net Income
P&L
+59.4%
$10.4M$16.5M

Net income grew 59.4% — bottom-line growth signals improving overall business health.

Capital Expenditure
Cash Flow
-57.5%
$64.0M$27.2M

Capex reduced 57.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Accounts Receivable
Balance Sheet
+37.9%
$61.4M$84.6M

Receivables surged 37.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Cash & Equivalents
Balance Sheet
+34.3%
$74.5M$100.1M

Cash position surged 34.3% — strong cash generation or capital raise providing significant financial cushion.

Stockholders Equity
Balance Sheet
+21.5%
$292.0M$354.6M

Equity base grew 21.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Gross Profit
P&L
+19.5%
$172.1M$205.6M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

SG&A Expense
P&L
+16.9%
$142.8M$167.0M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Revenue
P&L
+16.5%
$237.2M$276.3M

Revenue growing 16.5% — solid top-line momentum, watch margins for quality of growth.

Current Assets
Balance Sheet
+16.3%
$212.8M$247.4M

Current assets grew 16.3% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
Market for Registrant s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities 5 7 Item 6.
All other trade names, trademarks and service marks of other companies appearing in this Form 10-K are the property of their respective holders, including NexoBrid, which is a registered trademark of MediWound Ltd.
Business General Information Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets.
We have a highly differentiated portfolio of cell therapy and specialty biologic products that combines innovations in biology with medical technologies.
during the third quarter of 2024, and the Company began selling MACI Arthro instruments at that time.
+7 more — sign up free →
REMOVED
Market for Registrant s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities 58 Item 6.
We own various trademark registrations and applications, and unregistered trademarks, including Vericel Corporation, Epicel, MACI, MACI Arthro and our corporate logo.
Business General Information Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company and a leading provider of advanced therapies for the sports medicine and severe burn care markets.
Whether we are treating damaged cartilage or severe burns, we provide advanced therapies to repair serious injuries and restore lives.
Our highly differentiated portfolio of cell therapy and specialty biologic products combines innovations in biology with medical technologies.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →